NASDAQ:ARGX - argenx Stock Price, Forecast & News

argenx trades on the NASDAQ under the ticker symbol "ARGX."

argenx is scheduled to release their next quarterly earnings announcement on Tuesday, March 24th 2020. View Earnings Estimates for argenx.

14 brokers have issued 1 year price objectives for argenx's stock. Their forecasts range from $125.00 to $194.00. On average, they anticipate argenx's share price to reach $168.92 in the next twelve months. This suggests a possible upside of 4.3% from the stock's current price. View Analyst Price Targets for argenx.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for argenx in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for argenx.

News articles about ARGX stock have trended somewhat positive on Thursday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. argenx earned a daily sentiment score of 2.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for argenx.

Some companies that are related to argenx include Seattle Genetics (SGEN), NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), Qiagen (QGEN), BIO-TECHNE (TECH), BioNTech (BNTX), Moderna (MRNA), Repligen (RGEN), Acceleron Pharma (XLRN), bluebird bio (BLUE), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Adaptive Biotechnologies (ADPT), Ablynx (ABLYF) and Crispr Therapeutics (CRSP).

Based on aggregate information from My MarketBeat watchlists, some companies that other argenx investors own include GALAPAGOS NV/S (GLPG), AcelRx Pharmaceuticals (ACRX), Neurocrine Biosciences (NBIX), Netflix (NFLX), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Intellia Therapeutics (NTLA), Sangamo Therapeutics (SGMO), Amarin (AMRN) and Exelixis (EXEL).

(ARGX) raised $65 million in an IPO on Thursday, May 18th 2017. The company issued 3,600,000 shares at a price of $18.18 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

argenx's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (11.14%), Artisan Partners Limited Partnership (3.46%), Franklin Resources Inc. (1.64%), Capital World Investors (1.51%), Eaton Vance Management (1.08%) and Janus Henderson Group PLC (0.88%).

ARGX stock was sold by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Citigroup Inc., Pictet Asset Management Ltd., Driehaus Capital Management LLC, Lord Abbett & CO. LLC, AXA, Credit Suisse AG and Barclays PLC.

ARGX stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Jane Street Group LLC, Capital World Investors, Fiera Capital Corp, Franklin Resources Inc., Fairmount Funds Management LLC, Eventide Asset Management LLC and Jennison Associates LLC.

Shares of ARGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ARGX stock can currently be purchased for approximately $161.88.

argenx has a market capitalization of $6.17 billion and generates $25.37 million in revenue each year. The company earns $-78,700,000.00 in net income (profit) each year or ($2.35) on an earnings per share basis. argenx employs 103 workers across the globe.View Additional Information About argenx.

The official website for argenx is http://www.argenx.com/.

argenx's mailing address is Willemstraat 5, Breda P7, 4811 AH. The company can be reached via phone at 329-310-3400 or via email at [email protected]